GMP IPO Watch
1. The Business: From Middleman to Maker
Speciality Medicines isn't your average pharmacy distributor. They focus on high-value specialty formulations—drugs used for complex conditions like oncology (cancer), immunology, and neurology.
The Current Model: They currently act as a high-end wholesaler and exporter, reaching over 20 states in India and 35+ countries globally.
The Pivot: The primary reason for this IPO is to build an in-house R&D Center in Gujarat. This will allow them to develop their own products rather than just distributing others', significantly boosting their profit margins in the long run.
2. Subscription Status (Day 2 Midday Update)
As of March 23, 2026, the issue has seen a polarized response between institutional and retail investors:
Total Subscription: ~0.85x (Approaching full subscription).
NII (HNI) Category: 1.60x — This is the strongest segment, showing that "big ticket" investors are confident in the company's fundamentals.
Retail Category: 0.08x — Public participation remains low, likely due to the high entry barrier typical of SME IPOs.
QIB Category: 1.00x — Fully booked by institutional buyers.
3. IPO Timeline & Investment Details
Since this is a BSE SME listing, the lot sizes and investment amounts are higher than standard mainboard IPOs.
| Event / Detail | Important Dates & Info |
|---|---|
| IPO Closing Date | Tomorrow, Tuesday, March 24, 2026 |
| Price Band | ₹117 to ₹124 per share |
| Minimum Lot Size | 1,000 Shares |
| Minimum Investment | ₹2,48,000 (2 Lots for Retail) |
| Allotment Date | Wednesday, March 25, 2026 |
| Listing Date | Monday, March 30, 2026 (BSE SME) |
4. Grey Market Premium (GMP) Today
Current GMP: ₹0
Interpretation: The grey market is currently "flat," meaning the stock is expected to list near its issue price of ₹124. In the current volatile market, a ₹0 GMP isn't necessarily a "red flag"—it often indicates that speculators are staying away, leaving the field open for fundamental investors.
5. Financial Snapshot: A "Top-Line" Explosion
The company’s growth in the last year has been remarkable:
Revenue (FY25): ₹58.54 crore (More than double the ₹27.66 crore in FY24).
Profit (PAT): ₹8.61 crore (Up from ₹2.93 crore in FY24).
Efficiency: A very healthy Return on Equity (ROE) of 37.85% and a low Debt-to-Equity ratio of 0.17.
6. Investor Verdict: The Pros & Cons
The Bull Case (The "Pros"):
Low Valuation: At a P/E of 8.79x, it is priced much cheaper than industry peers like Remus Pharmaceuticals (~10x) or Trident Lifeline (~27x).
100% Fresh Issue: No promoters are selling their shares (no OFS). Every rupee raised goes back into the company's growth.
Asset-Light to R&D: The move into R&D could transform them from a low-margin distributor to a high-margin pharma player.
The Bear Case (The "Cons"):
SME Risk: SME stocks have lower liquidity, meaning it can be harder to sell your shares quickly after listing.
Geopolitical Sensitivity: With exports to 35+ countries, any global trade tension or supply chain issue hits their bottom line directly.
